UPMC Hillman Cancer Center Washington is a clinical research site located in Washington, Pennsylvania, United States 15301.
Crixeo Health Trust Score: 71/100 (FAIR). This profile has not yet been claimed by the site owner.
UPMC Hillman Cancer Center Washington has participated in 5 clinical trials with 1 currently active.
Therapeutic areas: HER2 Positive Breast Cancer, Early Breast Cancer, Primary Invasive Breast Cancer.
Sponsors: Seagen, a wholly owned subsidiary of Pfizer, Pfizer, Myriad Genetic Laboratories, Inc..
Trust Score: 71/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
UPMC Hillman Cancer Center Washington has a Crixeo Trust Score of 71/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
UPMC Hillman Cancer Center Washington has 5 clinical trials on record, with 1 currently active. Their work covers HER2 Positive Breast Cancer, Early Breast Cancer, Primary Invasive Breast Cancer.
Yes — UPMC Hillman Cancer Center Washington holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.